Skip to main content
Clinical Trials/NCT06386380
NCT06386380
Not Yet Recruiting
N/A

Adversity and Its Association With the Development and Expression of Rheumatic Diseases

National Institute of Medical Sciences and Nutrition, Salvador Zubiran0 sites110 target enrollmentJune 1, 2024

Overview

Phase
N/A
Intervention
Not specified
Conditions
RhA - Rheumatoid Arthritis
Sponsor
National Institute of Medical Sciences and Nutrition, Salvador Zubiran
Enrollment
110
Primary Endpoint
Adversity and senescence in patients with rheumatoid arthritis
Status
Not Yet Recruiting
Last Updated
last year

Overview

Brief Summary

Epidemiological evidence shows that adverse experiences, particularly, but not exclusively in childhood, are predictors of poor long-term health outcomes and certain social domains. In the field of rheumatic diseases, traumatic events, not only in childhood, have been associated with hospitalization, chronic pain, inflammation, worse outcomes, severity of the disease, and mortality. Some mechanisms proposed to explain the association between the experience of adversity and the development of chronic diseases include an impact on the physiology of immune system cells, gene expression due to DNA modification, and cellular senescence.

With this background, the investigators wonder if, for patients with rheumatoid arthritis, the presence of adversity understood as a history of violence in childhood and abuse due to suffering from rheumatoid arthritis is associated with markers of cellular senescence and with the severity of illness.

Detailed Description

To answer this question, the investigators proposed conducting a study on outpatients diagnosed with rheumatoid arthritis treated at the INCMNSZ. Patients who agree to participate will be asked to answer some questionnaires to report their perception of child abuse and abuse derived from suffering from rheumatoid arthritis, disease activity, disability, quality of life, anxiety, stress, depression, and resilience. Additionally, a peripheral blood sample will be taken to evaluate cellular senescence through CD27, CD28, and CD57 expression, the relative expression of the p16INK4a gene in CD3+ lymphocytes, HLA-DR, CD25, and CD69, and telomere length. Finally, the expression of the severity of the disease will be determined.

Registry
clinicaltrials.gov
Start Date
June 1, 2024
End Date
February 1, 2026
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
National Institute of Medical Sciences and Nutrition, Salvador Zubiran
Responsible Party
Principal Investigator
Principal Investigator

Virginia Pascual Ramos

Dr

National Institute of Medical Sciences and Nutrition, Salvador Zubiran

Eligibility Criteria

Inclusion Criteria

  • Patients with a rheumatoid arthritis diagnosis, according to their primary rheumatologist who agrees to participate

Exclusion Criteria

  • Patients with a not confirmed rheumatoid arthritis diagnosis

Outcomes

Primary Outcomes

Adversity and senescence in patients with rheumatoid arthritis

Time Frame: At inclusion (baseline moment) (cross-sectional study)]

To evaluate whether the presence of adversity (history of abuse in childhood and/or abuse associated with RD) is associated with markers of senescence in patients with rheumatoid arthritis.

Secondary Outcomes

  • Eexpression of the p16INK4a gene in CD3+(At inclusion (baseline moment) (cross-sectional study)])
  • Telomere length(At inclusion (baseline moment) (cross-sectional study)])

Similar Trials